Skip to main content
. Author manuscript; available in PMC: 2019 Nov 7.
Published in final edited form as: Hepatoma Res. 2019 Oct 13;5:38. doi: 10.20517/2394-5079.2019.013

Table 4.

Predictors of 10-year survival (all patients)

Univariate odds-ratio (95%CI) Multivariate odds-ratio (95%CI)
Age ≥ 65 0.29 (0.14–0.57) 0.33 (0.15–0.72)
Sex (Males) 1.71 (0.86–3.41)
Hepatitis B 1.30 (0.74–2.30)
Hepatitis C 1.21 (0.68–2.15)
Alcohol history 1.28 (0.72–2.29)
NASH/NAFLD 0.43 (0.16–1.17) 1.07 (0.32–3.52)
HCC found with surveillance 1.05 (0.50–2.21)
BMI ≥ 25 0.84 (0.48–1.50)
BMI ≥ 30 0.84 (0.40–1.75)
Smoking 0.81 (0.46–1.42)
Diabetes mellitus 0.28 (0.13–0.60) 0.28 (0.12–0.68)
Hyperlipidemia 0.60 (0.29–1.27)
Hypertension 0.36 (0.20–0.66) 0.66 (0.33–1.31)
Normal AFP 0.67 (0.38–1.18)
Size ≥ 5 cm 0.47 (0.26–0.84) 0.52 (0.14–1.91)
Met Milan criteria 1.86 (1.06–3.28) 0.69 (0.20–2.41)
Rupture 0.27 (0.06–1.22) 0.36 (0.07–1.85)

Significant values are in bold. NASH: non-alcoholic steatohepatitis; NAFLD: Non-alcoholic fatty liver disease; HCC: hepatocellular cancer; BMI: body mass index; AFP: alpha feto protein